From:  Extracellular vesicles as candidate mediators linking insulin resistance and metabolic dysfunction-associated steatotic liver disease

 Representative EV cargoes implicated in the relationship between insulin resistance and MASLD, with the experimental design underlying each claim.

EV cargoPrincipal sourceProposed target or pathwayReported effectDesign and strength of inference
miR-155Adipose tissue macrophagesRepression of PPAR-gammaGlucose intolerance and insulin resistance in lean recipients; reversed with lean-donor vesiclesAdoptive transfer, genetic deletion, marrow reconstitution, GW4869; strongest causal design in the field, murine only [43]
miR-122, miR-192, miR-27a/bAdipose tissue and liverPPAR-alpha (Ppara) in white adipose tissueGlucose intolerance, dyslipidaemia, adipose inflammation, hepatic steatosis after mimic-loaded transferLoaded-vesicle transfer with pharmacological rescue; causal within model, supraphysiological dosing [41]
Adipokine-bearing EVs (IL-6, MIF, MCP-1)Human adipose explantsInsulin-induced AKT phosphorylationReduced hepatic insulin signalling; response heterogeneous, a minority of donors showing the opposite effectEx vivo human explant vesicles on cell lines; associative, no in vivo endpoint [40]
let-7e-5pHepatocytes (Ggpps/Rab27A-dependent)Adipocyte lipogenic programmeIncreased adipocyte lipid accumulation; plasma levels track BMI and hepatic triglycerideMurine interventional plus human cross-sectional correlation [47]
TLR4 ligandsLipotoxic hepatocytesIslet macrophage TLR4Islet inflammation, impaired insulin secretionMurine, with genetic and pharmacological TLR4 dependence demonstrated [48]
Ceramide and sphingosine-1-phosphatePalmitate-stressed hepatocytesS1P receptor 1 on macrophagesMacrophage chemotaxis; cargo depletion abrogates the effectKnockout hepatocytes, chemotaxis assay, human plasma correlation [37, 49]
TRAILLipotoxic hepatocytes (DR5/ROCK1)Macrophage death receptor 5IL-1-beta and IL-6 induction; ROCK1 inhibition reduced vesicle release, injury and fibrosis in vivoIn vitro pathway inactivation plus in vivo pharmacological intervention [50]
CXCL10Lipotoxic hepatocytes (MLK3)Macrophage CXCR3Innate immune chemotaxis; macrophage-associated inflammation in murine MASHGenetic and pharmacological MLK3 inhibition; CXCL10-deficient models [51, 52]
miR-192-5p; miR-9-5pLipotoxic hepatocytesRictor/AKT/FoxO1M1 polarisation; serum miR-192-5p correlates with inflammatory activityMurine mechanism plus human serum correlation [53, 54]
miR-128-3pFat-laden hepatocytesStellate cell PPAR-gammaStellate activation, proliferation, chemotaxis; upregulated collagen I, alpha-SMA, TIMP-2Loss- and gain-of-function in cultured stellate cells; in vitro only [55, 56]

BMI: body mass index; CXCL10: C-X-C motif chemokine ligand 10; CXCR3: C-X-C motif chemokine receptor 3; DR5: death receptor 5; FoxO1: forkhead box protein O1; Ggpps: geranylgeranyl diphosphate synthase; IL-6: interleukin-6; MCP-1: monocyte chemoattractant protein-1; MIF: macrophage migration inhibitory factor; MLK3: mixed lineage kinase 3; Rab27A: Ras-related protein Rab-27A; ROCK1: Rho-associated coiled-coil-containing protein kinase 1; S1P: sphingosine-1-phosphate; TIMP-2: tissue inhibitor of metalloproteinases 2; TLR4: Toll-like receptor 4; TRAIL: tumour necrosis factor-related apoptosis-inducing ligand.